PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
91.74%
Some net income increase while CRVO is negative at -219.23%. John Neff would see a short-term edge over the struggling competitor.
-100.00%
Negative yoy D&A while CRVO is 96.09%. Joel Greenblatt would note a short-term EPS advantage unless competitor invests for future advantage.
100.00%
Deferred tax of 100.00% while CRVO is zero at 0.00%. Bruce Berkowitz would see a partial difference that can matter for future cash flow if large in magnitude.
-95.76%
Negative yoy SBC while CRVO is 0.00%. Joel Greenblatt would see less immediate dilution advantage if talent levels remain strong.
-167.13%
Both reduce yoy usage, with CRVO at -57.33%. Martin Whitman would find an industry or cyclical factor prompting leaner operational approaches.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-230.77%
Both negative yoy AP, with CRVO at -107.63%. Martin Whitman would find an overall trend toward paying down supplier credit in the niche.
-79.38%
Both reduce yoy usage, with CRVO at -65.24%. Martin Whitman would suspect an industry or cyclical factor pulling back on these items.
-151.83%
Negative yoy while CRVO is 105.53%. Joel Greenblatt would see a near-term net income or CFO stability advantage unless competitor invests or writes down more aggressively.
55.51%
Operating cash flow growth at 50-75% of CRVO's 79.56%. Martin Whitman would worry about lagging operational liquidity vs. competitor.
52.86%
CapEx growth of 52.86% while CRVO is zero at 0.00%. Bruce Berkowitz would see a mild cost burden that must yield returns in future revenue or margins.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
52.86%
We expand invests by 52.86% while CRVO is zero at 0.00%. Bruce Berkowitz sees a moderate outflow that must be justified by returns vs. competitor’s stable approach.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.